September 27, 2021Journal of the American College of Cardiology161 citationsOpen Access
View Full PaperThree- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension
Structured PICO
Does initial triple oral therapy improve pulmonary vascular resistance reduction by week 26 compared to initial double oral therapy in patients with newly diagnosed pulmonary arterial hypertension?
P
Population
Patients with newly diagnosed pulmonary arterial hypertension (PAH)
I
Intervention
Initial triple oral therapy
C
Comparator
Initial double oral therapy
O
Outcome
Reduction in pulmonary vascular resistance (PVR) by week 26surrogate
Initial triple oral therapy did not significantly improve PVR reduction at 26 weeks compared to double therapy in newly diagnosed PAH, though exploratory data suggest potential long-term benefits.
Abstract
In patients with newly diagnosed PAH, both treatment strategies markedly reduced PVR by week 26, with no significant difference between groups (primary endpoint not met). Exploratory analyses suggested a possible signal for improved long-term outcomes with initial triple versus initial double oral therapy.